KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Accumulated Expenses (2020 - 2025)

Royalty Pharma's Accumulated Expenses history spans 6 years, with the latest figure at $110.8 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 13.01% year-over-year to $110.8 million; the TTM value through Dec 2025 reached $110.8 million, up 13.01%, while the annual FY2025 figure was $110.8 million, 13.01% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $110.8 million at Royalty Pharma, up from $29.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $110.8 million in Q4 2025 and bottomed at $10.3 million in Q1 2021.
  • The 5-year median for Accumulated Expenses is $40.7 million (2021), against an average of $42.2 million.
  • The largest annual shift saw Accumulated Expenses skyrocketed 204.98% in 2024 before it decreased 24.39% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $57.7 million in 2021, then decreased by 6.13% to $54.2 million in 2022, then fell by 4.58% to $51.7 million in 2023, then skyrocketed by 89.74% to $98.1 million in 2024, then grew by 13.01% to $110.8 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Accumulated Expenses are $110.8 million (Q4 2025), $29.0 million (Q3 2025), and $85.6 million (Q2 2025).